| A paradigm shift in cancer immunotherapy: from enhancement to normalization MF Sanmamed, L Chen Cell 175 (2), 313-326, 2018 | 1217 | 2018 |
| Cytokines in clinical cancer immunotherapy P Berraondo, MF Sanmamed, MC Ochoa, I Etxeberria, MA Aznar, ... British journal of cancer 120 (1), 6-15, 2019 | 955 | 2019 |
| Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3 J Wang, MF Sanmamed, I Datar, TT Su, L Ji, J Sun, L Chen, Y Chen, ... Cell 176 (1), 334-347. e12, 2019 | 673 | 2019 |
| Direct effects of type I interferons on cells of the immune system S Hervas-Stubbs, JL Perez-Gracia, A Rouzaut, MF Sanmamed, A Le Bon, ... Clinical Cancer Research 17 (9), 2619-2627, 2011 | 631 | 2011 |
| Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer S Gettinger, J Choi, K Hastings, A Truini, I Datar, R Sowell, A Wurtz, ... Cancer discovery 7 (12), 1420-1435, 2017 | 604 | 2017 |
| Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma KA Schalper, ME Rodriguez-Ruiz, R Diez-Valle, A López-Janeiro, ... Nature medicine 25 (3), 470-476, 2019 | 537 | 2019 |
| Immunotherapy in non–small cell lung cancer: facts and hopes DB Doroshow, MF Sanmamed, K Hastings, K Politi, DL Rimm, L Chen, ... Clinical Cancer Research 25 (15), 4592-4602, 2019 | 535 | 2019 |
| Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy J Wang, J Sun, LN Liu, DB Flies, X Nie, M Toki, J Zhang, C Song, M Zarr, ... Nature medicine 25 (4), 656-666, 2019 | 513 | 2019 |
| CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity Á Teijeira, S Garasa, M Gato, C Alfaro, I Migueliz, A Cirella, C de Andrea, ... Immunity 52 (5), 856-871. e8, 2020 | 475 | 2020 |
| Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies C Chester, MF Sanmamed, J Wang, I Melero Blood, The Journal of the American Society of Hematology 131 (1), 49-57, 2018 | 405 | 2018 |
| Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients MF Sanmamed, JL Perez-Gracia, KA Schalper, JP Fusco, A Gonzalez, ... Annals of Oncology 28 (8), 1988-1995, 2017 | 398 | 2017 |
| Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs) C Alfaro, A Teijeira, C Oñate, G Perez, MF Sanmamed, MP Andueza, ... Clinical Cancer Research 22 (15), 3924-3936, 2016 | 366 | 2016 |
| Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors KA Schalper, M Carleton, M Zhou, T Chen, Y Feng, SP Huang, AM Walsh, ... Nature medicine 26 (5), 688-692, 2020 | 350 | 2020 |
| Interleukin-8 in cancer pathogenesis, treatment and follow-up C Alfaro, MF Sanmamed, ME Rodríguez-Ruiz, Á Teijeira, C Oñate, ... Cancer treatment reviews 60, 24-31, 2017 | 319 | 2017 |
| Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with … MF Sanmamed, S Fernández-Landázuri, C Rodríguez, R Zárate, ... Clinical chemistry 61 (1), 297-304, 2015 | 274 | 2015 |
| Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non–small cell lung cancer using spatially resolved and multiparametric single-cell analysis I Datar, MF Sanmamed, J Wang, BS Henick, J Choi, T Badri, W Dong, ... Clinical Cancer Research 25 (15), 4663-4673, 2019 | 258 | 2019 |
| Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS MF Sanmamed, F Pastor, A Rodriguez, JL Perez-Gracia, ... Seminars in oncology 42 (4), 640-655, 2015 | 256 | 2015 |
| Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins MF Sanmamed, O Carranza-Rua, C Alfaro, C Onate, S Martín-Algarra, ... Clinical Cancer Research 20 (22), 5697-5707, 2014 | 242 | 2014 |
| Paradigms on immunotherapy combinations with chemotherapy D Salas-Benito, JL Pérez-Gracia, M Ponz-Sarvisé, ME Rodriguez-Ruiz, ... Cancer discovery 11 (6), 1353-1367, 2021 | 223 | 2021 |
| IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy T Zhou, W Damsky, OE Weizman, MK McGeary, KP Hartmann, CE Rosen, ... Nature 583 (7817), 609-614, 2020 | 223 | 2020 |
